... of a federal grand jury investigation related to activities surrounding the 2003 commercial launch of its drug Cardizem, which treats hypertension. ...
The most dangerous drugs in this group are a class called calcium channel blockers, such as diltiazem or cardizem. No. 2 on the list is narcotics, ...
... about $85 million to settle a US securities class action suit that stretched back more than 4 years involving its Wellbutrin XL and Cardizem LA products.
The case centered on claims Biovail made regarding its two key products, Cardizem LA and Wellbutrin XL. Still, the company said the pact "contains no ...
... former chairperson and chief executive Melnyk and the others of making misleading statements about the launch of Biovail's Cardizem LA blood-pressure ...
TO), which resolved a long drawn-out patent suit related to Andrx's attempt to market a generic version of heart drug Cardizem LA, Biovail's once-daily ...
Last week, Biovail reached an agreement with Watson Pharmaceuticals Inc. to delay until 2009 a generic competitor to its Cardizem heart drug. ...
Still, he said the deal does inject a bit of certainty into Watson's income statement and moves Cardizem LA onto investor radar screens. ...
Under the terms of the settlement agreement, Biovail has granted Watson an exclusive license to its US patents covering Cardizem(R) LA for a generic version ...
Under the terms of the settlement, Biovail will receive a royalty based on sales of Watson's generic formulation of Cardizem. Watson also won't start ...